2025-09-25 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data, presented in English with a focus on key numbers and concise analysis.

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation and perfusion systems for transplantation.

## TMDX Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 18.46%
*   **VOO Cumulative Return:** 46.38%
*   **Absolute Divergence (Current):** -27.92% (TMDX is lagging VOO)
*   **Relative Divergence:** 61.0 (This indicates that the current divergence is positioned at the 61st percentile within the historical range of divergence, meaning it's relatively moderate compared to its historical extremes).

**Alpha and Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2019-2021  | -23.0%  | 71.6%   | -51.0%  | -0.0   | 0.7    |
| 2020-2022  | 32.0%   | 97.9%   | 36.0%   | -0.0   | 2.1    |
| 2021-2023  | 10.0%   | 97.9%   | -1.0%   | 0.0    | 2.7    |
| 2022-2024  | 70.0%   | 97.9%   | 46.0%   | 0.0    | 2.1    |
| 2023-2025  | 1.0%    | 98.9%   | -38.0%  | 0.3    | 4.0    |

**Analysis:**

*   **Underperformance:** TMDX has significantly underperformed the S&P 500.
*   **Volatility:** MDD is exceptionally high, indicating very high price swings.
*   **Alpha:** Alpha fluctuates significantly, suggesting inconsistent outperformance relative to the market.  The recent period (2023-2025) shows a large negative alpha, indicating underperformance compared to expectations based on its beta.
*   **Beta:** Beta is generally low, indicating low correlation with market movement (Beta around 0 indicates there is close to zero correlation with the market, beta 0.3 means that for every 1% move of the market (VOO), TMDX moves 0.3% on average).
*   **Capitalization:** Market capitalization has grown significantly over the period, indicating company growth.

### 2. Recent Price Action

*   **Current Price:** \$116.9
*   **Previous Close:** \$120.53
*   **Price Change:** -\$3.01 (-3.01%) **(Significant Drop)**
*   **5-Day Moving Average:** \$121.05
*   **20-Day Moving Average:** \$114.0
*   **60-Day Moving Average:** \$117.4891

**Analysis:**

*   **Price Decline:** The recent price drop is significant, indicating potential negative sentiment or news.
*   **Moving Averages:** The price is below the 5-day and 60-day moving averages but above the 20-day, suggesting a short-term downtrend but potential support around the 20-day MA. The close price (\$116.9) being under the 60-day Moving Average (\$117.4891) may indicate a further drop to the 20-day moving average (\$114.0).

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 62.87 (Approaching Overbought)
*   **PPO:** 1.17 (Positive Trend)
*   **Hybrid Signal:** cash_1%_Buy 50% of cash (4 shares - Caution - MRI:0.43)
*   **Delta_Previous_Relative_Divergence:** 5.1 (+) (Short-Term Increase)
*   **Expected Return:** 67.5% (Long-Term, vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a medium level of market risk.
*   **RSI:** The RSI is approaching overbought territory, suggesting the stock may be due for a pullback.
*   **PPO:** The positive PPO suggests a positive price trend.
*   **Hybrid Signal:** The algorithm suggests a very small allocation (1% cash) to buying, but with caution due to the MRI.
*   **Delta_Previous_Relative_Divergence:** The recent increase in relative divergence suggests short-term outperformance *relative* to its recent history.
*   **Expected Return:** The high expected return suggests analysts believe the stock has significant long-term upside potential compared to the S&P 500.

### 4. Recent News & Events

*   **Positive Coverage:** Several articles highlight TransMedics as a strong growth stock and potentially undervalued.
*   **Mercedes-Benz Partnership:** The partnership with Mercedes-Benz for organ transport is a significant positive development, indicating innovation and expansion.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.82)
*   **Target Price:** Average: \$140.67, High: \$170.00, Low: \$114.00
*   **Rating Changes:** No recent changes noted.

**Analysis:**

*   **Positive Outlook:** Analysts generally have a positive outlook on the stock, with a "Buy" consensus.
*   **Upside Potential:** The average target price suggests significant upside potential from the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:**

*   **Earnings Beats:** TMDX has consistently beaten EPS estimates in recent quarters. The EPS from 2025-07-30 and 2025-05-08 are significantly above the expected EPS.
*   **Positive Trend:** This suggests strong financial performance and positive earnings momentum.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | \$0.16B  | 61.38%        |
| 2025-03-31 | \$0.14B  | 61.47%        |
| 2024-12-31 | \$0.12B  | 59.21%        |
| 2024-09-30 | \$0.11B  | 55.94%        |
| 2024-06-30 | \$0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | \$0.32B  | 10.97% |
| 2025-03-31 | \$0.27B  | 9.64%  |
| 2024-12-31 | \$0.23B  | 3.00%  |
| 2024-09-30 | \$0.21B  | 2.01%  |
| 2024-06-30 | \$0.19B  | 6.42%  |

**Analysis:**

*   **Revenue Growth:** Revenue is consistently increasing, indicating business expansion.
*   **High Profit Margins:** High profit margins (above 55%) indicate a strong and efficient business model.
*   **Increasing Equity:** Increasing equity suggests the company is building its financial foundation.
*   **Improving ROE:** ROE is generally improving, indicating better profitability on shareholder equity.

### 7. 종합 Analysis (Overall Assessment)

**Summary:**

TransMedics (TMDX) presents a mixed picture. While the company shows strong fundamentals with increasing revenue, high profit margins, consistent earnings beats, and positive analyst ratings, it has significantly underperformed the S&P 500 in terms of stock returns. The recent price drop and high volatility are concerning.

**Key Positives:**

*   **Strong Financial Performance:**  Consistent revenue growth, high profit margins, and increasing equity.
*   **Earnings Beats:** Consistently exceeding EPS estimates.
*   **Positive Analyst Outlook:** "Buy" consensus with significant upside potential in target prices.
*   **Innovation:** Partnership with Mercedes-Benz indicates forward-thinking strategy.
*   **High Expected Return:** Long-term return is 67.5% compared to S&P 500.

**Key Negatives:**

*   **Underperformance:** Significantly lagging the S&P 500 in terms of stock returns.
*   **High Volatility:** MDD is very high, indicating significant price swings.
*   **Recent Price Drop:** The recent price decline is a cause for concern.

**Recommendation:**

Given the recent price drop and underperformance, caution is advised. The positive fundamentals and analyst outlook suggest long-term potential, but the high volatility and recent price action warrant careful monitoring. The hybrid signal suggesting a small buy position with caution seems appropriate. Further research is needed to understand the cause of the recent price drop and to assess whether the underperformance trend is likely to continue.
